Published in Allergy Asthma Immunol Res on February 25, 2013
Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med (2004) 3.16
Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol (2001) 2.38
The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med (1990) 2.35
Diagnosis of Hymenoptera venom allergy. Allergy (2005) 2.34
Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol (1996) 2.13
A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med (1978) 2.08
Epidemiology of insect venom sensitivity. JAMA (1989) 1.83
Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol (2008) 1.77
Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet (2001) 1.68
Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy (2009) 1.62
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol (2009) 1.57
Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet (2003) 1.54
Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol (1997) 1.46
Immunotherapy improves health-related quality of life of adult patients with dermal reactions following yellow jacket stings. Clin Exp Allergy (2009) 1.44
Insect venom allergy: diagnosis and treatment. J Allergy Clin Immunol (1984) 1.37
Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy. J Allergy Clin Immunol (2004) 1.35
Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol (2011) 1.21
The Hymenoptera venom study I, 1979-1982: demographics and history-sting data. J Allergy Clin Immunol (1988) 1.16
Clinical practice. Hypersensitivity to hymenoptera stings. N Engl J Med (2004) 1.14
Epidemiology of insect-venom anaphylaxis. Curr Opin Allergy Clin Immunol (2008) 1.14
A population-based epidemiologic analysis of deaths from anaphylaxis in Florida. Allergy (2008) 1.12
Regimens of Hymenoptera venom immunotherapy. Ann Intern Med (1980) 1.12
Insect sting anaphylaxis. Immunol Allergy Clin North Am (2007) 1.08
Expanding habitat of the imported fire ant (Solenopsis invicta): a public health concern. J Allergy Clin Immunol (2000) 1.05
Bee, wasp and ant venomics pave the way for a component-resolved diagnosis of sting allergy. J Proteomics (2009) 1.05
Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol (2001) 1.03
Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol (2004) 1.03
The Hymenoptera venom study. III: Safety of venom immunotherapy. J Allergy Clin Immunol (1990) 1.02
Epidemiology of Hymenoptera allergy. Curr Opin Allergy Clin Immunol (2002) 1.01
Allergens in Hymenoptera venom. XXI. Cross-reactivity and multiple reactivity between fire ant venom and bee and wasp venoms. J Allergy Clin Immunol (1988) 1.00
Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol (2008) 1.00
Venom immunotherapy: 10 years of experience with administration of single venoms and 50 micrograms maintenance doses. J Allergy Clin Immunol (1992) 0.98
Fatal anaphylaxis in the UK, 1992-2001. Novartis Found Symp (2004) 0.96
Prolonged maintenance interval in hymenoptera venom immunotherapy. J Allergy Clin Immunol (1981) 0.95
Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy (1993) 0.95
Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol (2000) 0.94
Epidemiological study of the prevalence of allergic reactions to Hymenoptera in a rural population in the Mediterranean area. Clin Exp Allergy (1999) 0.93
Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol (1997) 0.92
Anaphylactic deaths in Auckland, New Zealand: a review of coronial autopsies from 1985 to 2005. Pathology (2006) 0.90
Insect sting fatality 9 years after venom treatment (venom allergy, fatality). J Allergy Clin Immunol (2001) 0.89
Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy (1979) 0.87
Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol (2006) 0.87
Imported fire ant immunotherapy: effectiveness of whole body extracts. J Allergy Clin Immunol (1992) 0.87
Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol (2002) 0.87
Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol (1998) 0.87
Emergency treatment and prevention of insect-sting anaphylaxis. Curr Opin Allergy Clin Immunol (2006) 0.86
The Hymenoptera venom study. II: Skin test results and safety of venom skin testing. J Allergy Clin Immunol (1989) 0.85
Venom immunotherapy in the Hymenoptera-allergic pregnant patient. J Allergy Clin Immunol (1990) 0.85
Systemic reactions to stinging ants. J Allergy Clin Immunol (1974) 0.84
Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol (1993) 0.84
Timing of venom skin tests and IgE determinations after insect sting anaphylaxis. J Allergy Clin Immunol (1997) 0.84
Venom immunotherapy reduces large local reactions to insect stings. J Allergy Clin Immunol (2009) 0.83
Venom skin tests in insect-allergic and insect-nonallergic populations. J Allergy Clin Immunol (1985) 0.83
The natural history of exposure to the imported fire ant (Solenopsis invicta). J Allergy Clin Immunol (1995) 0.83
Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol (1998) 0.82
Discontinuing venom immunotherapy. Curr Opin Allergy Clin Immunol (2001) 0.82
Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol (2004) 0.82
Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy (1994) 0.81
Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol (1991) 0.81
Insect allergy in children. Curr Opin Allergy Clin Immunol (2006) 0.80
Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J Allergy Clin Immunol (2008) 0.80
Systemic reactions during maintenance immunotherapy with honey bee venom. Ann Allergy (1988) 0.79
Anaphylaxis to venom without IgE antibody. Allergy (2000) 0.79
Prospective observations on stopping prolonged venom immunotherapy. J Allergy Clin Immunol (1989) 0.79
Studies of coexisting honeybee and vespid-venom sensitivity. J Allergy Clin Immunol (1984) 0.79
Increasing cost of epinephrine autoinjectors. J Allergy Clin Immunol (2012) 0.79
Hymenoptera stings in conscripts. Allergy (1997) 0.78
Patients with negative skin tests. Curr Opin Allergy Clin Immunol (2002) 0.77
Clinical Features and the Diagnostic Value of Component Allergen-Specific IgE in Hymenoptera Venom Allergy. Allergy Asthma Immunol Res (2012) 0.76
Treatment of local skin response to imported fire ant sting. South Med J (1981) 0.76
Hypersensitivity to the imported fire ant in Florida. Report of 104 cases. J Fla Med Assoc (1977) 0.76
Allergens of the imported fire ant. J Allergy Clin Immunol (1988) 0.76
Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious. J Allergy Clin Immunol (2001) 0.76
A modified ultrarush insect venom immunotherapy protocol for children. Allergy Asthma Proc (2006) 0.75
Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol (2004) 5.80
Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med (2004) 2.06
Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol (2010) 1.67
Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy (2009) 1.65
Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol (2002) 1.62
Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. Mayo Clin Proc (2002) 1.56
NLRP3 deletion protects from hyperoxia-induced acute lung injury. Am J Physiol Cell Physiol (2013) 1.46
Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol (2008) 1.46
Exotic pet allergy. J Allergy Clin Immunol (2008) 1.41
2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol (2012) 1.36
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol (2013) 1.33
NALP-3 inflammasome silencing attenuates ceramide-induced transepithelial permeability. J Cell Physiol (2012) 1.32
World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol (2013) 1.31
Mechanism of cigarette smoke condensate-induced acute inflammatory response in human bronchial epithelial cells. Respir Res (2002) 1.30
Allergic diseases and asthma: a major global health concern. Curr Opin Allergy Clin Immunol (2012) 1.26
ARIA update: I--Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol (2006) 1.26
Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. PLoS One (2012) 1.25
Diagnosis and Rationale for Action Against Cow's Milk Allergy (DRACMA): a summary report. J Allergy Clin Immunol (2010) 1.24
Natriuretic peptide receptor a as a novel anticancer target. Cancer Res (2008) 1.14
2'-5' Oligoadenylate synthetase plays a critical role in interferon-gamma inhibition of respiratory syncytial virus infection of human epithelial cells. J Biol Chem (2002) 1.09
Epinephrine: the drug of choice for anaphylaxis-a statement of the world allergy organization. World Allergy Organ J (2008) 1.04
Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther (2002) 1.04
Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03
Multifunctional magnetic nanoparticles for targeted delivery. Nanomedicine (2009) 1.03
Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Nanomedicine (2007) 1.01
ERK-1/2 activity is required for efficient RSV infection. FEBS Lett (2004) 1.01
Chitosan IFN-gamma-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma. Genet Vaccines Ther (2003) 0.99
Respiratory syncytial virus infection activates STAT signaling in human epithelial cells. Biochem Biophys Res Commun (2003) 0.96
Thiolated chitosan/DNA nanocomplexes exhibit enhanced and sustained gene delivery. Pharm Res (2006) 0.92
Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor. Genet Vaccines Ther (2008) 0.92
Adenovirus-mediated interferon gamma gene therapy for allergic asthma: involvement of interleukin 12 and STAT4 signaling. Hum Gene Ther (2002) 0.91
Natriuretic peptides and genesis of asthma: an emerging paradigm? J Allergy Clin Immunol (2004) 0.90
Nanoparticle-mediated gene delivery: state of the art. Expert Opin Biol Ther (2004) 0.90
Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery. Genet Vaccines Ther (2004) 0.89
Interleukin-13 signaling and its role in asthma. World Allergy Organ J (2011) 0.88
Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. Genet Vaccines Ther (2007) 0.88
Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice. Virol J (2006) 0.88
Primary gastrointestinal lymphangiectasia presenting as cryptococcal meningitis. Ann Allergy Asthma Immunol (2007) 0.88
Asthma and comorbidities. Curr Opin Allergy Clin Immunol (2013) 0.88
Thiolated chitosan nanoparticles enhance anti-inflammatory effects of intranasally delivered theophylline. Respir Res (2006) 0.87
An immunocompromised BALB/c mouse model for respiratory syncytial virus infection. Virol J (2005) 0.86
Prick puncture skin tests and serum specific IgE as predictors of nasal challenge response to dermatophagoides pteronyssinus in older adults. Ann Allergy Asthma Immunol (2008) 0.86
Immunobiology of grass pollen allergens. Curr Allergy Asthma Rep (2005) 0.85
Allergen prick-puncture skin testing in the elderly. Drugs Aging (2003) 0.85
Allergen immunotherapy: a history of the first 100 years. Curr Opin Allergy Clin Immunol (2011) 0.84
World Allergy Organization guidelines for prevention of allergy and allergic asthma. Int Arch Allergy Immunol (2004) 0.84
Modulation of lung inflammation by vessel dilator in a mouse model of allergic asthma. Respir Res (2009) 0.84
Protein kinase C-alpha activity is required for respiratory syncytial virus fusion to human bronchial epithelial cells. J Virol (2004) 0.84
Mechanism of bronchoprotective effects of a novel natriuretic hormone peptide. J Allergy Clin Immunol (2004) 0.83
Do hypoallergenic cats and dogs exist? Ann Allergy Asthma Immunol (2012) 0.83
Atrial natriuretic peptide gene transfer by means of intranasal administration attenuates airway reactivity in a mouse model of allergic sensitization. J Allergy Clin Immunol (2002) 0.82
Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol (2013) 0.82
Adverse effects and fatalities associated with subcutaneous allergen immunotherapy. Clin Allergy Immunol (2008) 0.82
Serum total IgE and specific IgE to Dermatophagoides pteronyssinus, but not eosinophil cationic protein, are more likely to be elevated in elderly asthmatic patients. Allergy Asthma Proc (2004) 0.82
Systemic reactions to subcutaneous allergen immunotherapy and the response to epinephrine. Allergy Asthma Proc (2011) 0.81
Intranasal IL-12 produces discreet pulmonary and systemic effects on allergic inflammation and airway reactivity. Int Immunopharmacol (2003) 0.81
Health economics of allergen-specific immunotherapy in the United States. J Allergy Clin Immunol (2011) 0.80
Patient characteristics associated with allergen immunotherapy initiation and adherence. J Allergy Clin Immunol (2010) 0.80
Mite and cockroach proteases activate p44/p42 MAP kinases in human lung epithelial cells. Clin Mol Allergy (2003) 0.80
Regulating the Regulators: microRNA and Asthma. World Allergy Organ J (2011) 0.80
Aspirin-exacerbated asthma. Allergy Asthma Clin Immunol (2008) 0.79
Temporomandibular dysfunction: an often overlooked cause of chronic headaches. Ann Allergy Asthma Immunol (2007) 0.79
Safety of binodenoson, a selective adenosine A2A receptor agonist vasodilator pharmacological stress agent, in healthy subjects with mild intermittent asthma. Circ Cardiovasc Imaging (2009) 0.79
Increasing cost of epinephrine autoinjectors. J Allergy Clin Immunol (2012) 0.79
An update on the safety of specific immunotherapy. Curr Opin Allergy Clin Immunol (2008) 0.79
Treatment of Hymenoptera venom allergy: an update. Curr Opin Allergy Clin Immunol (2014) 0.79
The Role of Aging in Idiopathic Pulmonary Fibrosis. Lung (2015) 0.78
Immunotherapy for hymenoptera venom hypersensitivity. Clin Allergy Immunol (2008) 0.78
[Immunotherapy in Latin America. From the past to the future]. Rev Alerg Mex (2008) 0.78
Oxymetazoline hydrochloride combined with mometasone nasal spray for persistent nasal congestion (pilot study). World Allergy Organ J (2011) 0.78
Indoor allergen assessments: a call for universal standards. J Allergy Clin Immunol (2006) 0.77
We call for iCAALL: International Collaboration in Asthma, Allergy and Immunology. J Allergy Clin Immunol (2012) 0.77
Adverse effects and fatalities associated with subcutaneous allergen immunotherapy. Clin Allergy Immunol (2004) 0.77
Mite allergens. Clin Allergy Immunol (2008) 0.77
Immunotherapy for hymenoptera venom and biting insect hypersensitivity. Clin Allergy Immunol (2004) 0.77
Melaleuca tree and respiratory disease. Ann Allergy Asthma Immunol (2002) 0.77
Inflammasome Inhibition Suppresses Alveolar Cell Permeability Through Retention of Neuregulin-1 (NRG-1). Cell Physiol Biochem (2015) 0.76
We Call for iCAALL: International Collaboration in Asthma, Allergy and Immunology. World Allergy Organ J (2012) 0.76
The impact of rhinosinusitis on asthma. Curr Allergy Asthma Rep (2003) 0.76
Symptomatic Primary Selective Immunoglobulin M Deficiency with Nonprotective Pneumococcal Titers Responsive to Subcutaneous Immunoglobulin Treatment. Int Arch Allergy Immunol (2016) 0.75
Mite allergens. Clin Allergy Immunol (2004) 0.75
Mass psychogenic illness presenting as acute stridor in an adolescent female cohort. Ann Otol Rhinol Laryngol (2007) 0.75
ROMO1 links oxidative stress to mitochondrial integrity. J Cell Commun Signal (2014) 0.75
Outcomes of allergy to insect stings in children, with and without venom immunotherapy. J Pediatr (2005) 0.75
Oral curcumin supplementation in patients with atopic asthma. Allergy Rhinol (Providence) (2011) 0.75
Respiratory syncytial virus infection: from biology to therapy: a perspective. World Allergy Organ J (2008) 0.75
Weed pollen allergens. Clin Allergy Immunol (2008) 0.75
The myth of hypoallergenic dogs (and cats). J Allergy Clin Immunol (2012) 0.75
Respiratory syncytial virus: immunopathology and control. Expert Rev Clin Immunol (2006) 0.75
EZH2, the moderator in the discussion between methyltransferases at histone H3? J Cell Commun Signal (2014) 0.75
We call for iCAALL: International Collaboration for Asthma, Allergy and Immunology. Ann Allergy Asthma Immunol (2012) 0.75
Important Florida botanical aeroallergens. Allergy Asthma Proc (2010) 0.75
Allergic and nonallergic reactions to nitroglycerin. Allergy Asthma Proc (2006) 0.75
Instructions and consent forms for subcutaneous allergen immunotherapy. Clin Allergy Immunol (2008) 0.75
Osteoporosis and asthma. Ann Allergy Asthma Immunol (2006) 0.75
The allergy archives: pioneers and milestones. J Allergy Clin Immunol (2006) 0.75
Nocturnal asthma. Strategies that put it to rest. Adv Nurse Pract (2002) 0.75
Visceral sensitivity in gastroesophageal reflux. Dig Dis Sci (2002) 0.75
Weed pollen allergens. Clin Allergy Immunol (2004) 0.75
Inhaled mometasone furoate improves health-related quality of life in patients with persistent asthma. J Asthma (2008) 0.75